YONKERS, NY--(Marketwired - Aug 11, 2015) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced that an independent Data and Safety Monitoring Board (DSMB) recommended the continuation of the CF-301 Phase 1 study. Thus far, the study has successfully completed two dose levels out of the currently planned four, and ContraFect expects to complete the study by year-end. If the results of the Phase 1 study in healthy volunteers are favorable, ContraFect plans to advance CF-301 into Phase 2 study next year in patients with staph bloodstream infections, including MRSA.
"ContraFect is pleased to have made progress in this important initial stage of development for CF-301, the first lysin allowed by the FDA to enter human clinical trials, targeting drug-resistant Staph infections, including MRSA," said Julia P. Gregory, ContraFect's Chief Executive Officer. "Novel approaches, like CF-301, with activity against drug-resistant bacteria and biofilms offer great potential to successfully treat these current life-threatening infections."